Literature DB >> 23263547

The importance of rheumatology biologic registries in Latin America.

Maria de la Vega1, Hellen M da Silveira de Carvalho, Lucio Ventura Ríos, Maria V Goycochea Robles, Gustavo C Casado.   

Abstract

Rheumatoid arthritis is a systemic inflammatory disorder characterized by joint articular pain and disability. Although there is scarcity of data available on the incidence and prevalence of RA in Latin America, there is a growing recognition of this disease where chronic diseases are on the rise and infectious disease on the decline. RA is a substantial burden to patients, society, and the healthcare system. The heterogeneity identified within RA presents an opportunity for personalized medicine, especially in regions with such demographic diversity as that of Latin America. To understand the long-term effects of treatment for RA especially on safety, registries have been established, a number of which have been created in Latin America. Despite their weaknesses (e.g., lack of controls and randomization), registries have provided additional and complementary information on the use of biologics in clinical practice in Latin America and other regions. Although certain challenges remain in the implementation and maintenance of registries, they continue to provide real-life data to clinical practice contributing to improved patient care.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23263547     DOI: 10.1007/s00296-012-2610-2

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  42 in total

1.  [Update of BIOBADASER].

Authors:  Loreto Carmona
Journal:  Reumatol Clin       Date:  2009-03-27

2.  BiobadaBrasil: Brazilian biologic registry.

Authors:  David C Titton
Journal:  Rev Bras Reumatol       Date:  2011 Mar-Apr

3.  A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries.

Authors:  Jeffrey R Curtis; Archana Jain; Johan Askling; S Louis Bridges; Loreto Carmona; William Dixon; Axel Finckh; Kimme Hyrich; Jeffrey D Greenberg; Joel Kremer; Joachim Listing; Kaleb Michaud; Ted Mikuls; Nancy Shadick; Daniel H Solomon; Michael E Weinblatt; Fred Wolfe; Angela Zink
Journal:  Semin Arthritis Rheum       Date:  2010-08       Impact factor: 5.532

4.  Brazilian biologic registry: BiobadaBrasil implementation process and preliminary results.

Authors:  David C Titton; Ines Guimarães Silveira; Paulo Louzada-Junior; Andre L Hayata; Hellen Mary S Carvalho; Roberto Ranza; Lucila S Rezende; Geraldo Castelar Pinheiro; Jair Licio F Santos; Jose Roberto Miranda; Jozelio Freitas Carvalho; Manoel Barros Bertolo; Marlene Freire; Morton A Scheinberg; Thelma L Skare; Vander Fernandes; Washington Bianchi; Ieda Maria M Laurindo
Journal:  Rev Bras Reumatol       Date:  2011 Mar-Apr

Review 5.  Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies.

Authors:  P Miossec; C L Verweij; L Klareskog; C Pitzalis; A Barton; F Lekkerkerker; S Reiter; A Laslop; F Breedveld; E Abadie; B Flamion; W Dere; S Mpofu; N Goel; D Ethgen; B Mitlak; S Ormarsdóttir; R Rao; Y Tsouderos; J-Y Reginster
Journal:  Ann Rheum Dis       Date:  2011-07-22       Impact factor: 19.103

6.  Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register.

Authors:  Suzanne M M Verstappen; Yvonne King; Kath D Watson; Deborah P M Symmons; Kimme L Hyrich
Journal:  Ann Rheum Dis       Date:  2011-02-28       Impact factor: 19.103

7.  Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.

Authors:  P Geborek; M Crnkic; I F Petersson; T Saxne
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

8.  A majority of Brazilian patients with rheumatoid arthritis HLA-DRB1 alleles carry both the HLA-DRB1 shared epitope and anti-citrunillated peptide antibodies.

Authors:  P Louzada-Júnior; M V C Freitas; R D R Oliveira; N H S Deghaide; R A Conde; M B Bertolo; E A Donadi
Journal:  Braz J Med Biol Res       Date:  2008-05-31       Impact factor: 2.590

9.  Latitude gradient influences the age of onset in rheumatoid arthritis patients.

Authors:  Cesar Ramos-Remus; Gabriela Sierra-Jimenez; Kenneth Skeith; Francisco J Aceves-Avila; Anthony S Russell; Robert Offer; Juan E Olguin-Redes; Joanne Homik; Lourdes Sanchez; Adriana Sanchez-Ortiz; Gregorio Navarro-Cano
Journal:  Clin Rheumatol       Date:  2007-07-24       Impact factor: 2.980

10.  Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.

Authors:  Merete Lund Hetland; Ib Jarle Christensen; Ulrik Tarp; Lene Dreyer; Annette Hansen; Ib Tønder Hansen; Gina Kollerup; Louise Linde; Hanne M Lindegaard; Uta Engling Poulsen; Annette Schlemmer; Dorte Vendelbo Jensen; Signe Jensen; Gisela Hostenkamp; Mikkel Østergaard
Journal:  Arthritis Rheum       Date:  2010-01
View more
  4 in total

1.  Systematic and progressive implementation of the centers of excellence for rheumatoid arthritis: a methodological proposal.

Authors:  Pedro Santos-Moreno; Carlo V Caballero-Uribe; Maria Loreto Massardo; Claudio Galarza Maldonado; Enrique R Soriano; Carlos Pineda; Mario Cardiel; Juan Alberto Benavides; Paula Andrea Beltrán
Journal:  Clin Rheumatol       Date:  2017-08-24       Impact factor: 2.980

2.  PANLAR consensus statement on biosimilars.

Authors:  S C Kowalski; J A Benavides; P A B Roa; C Galarza-Maldonado; C V Caballero-Uribe; E R Soriano; C Pineda; V F Azevedo; G Avila-Pedretti; A M Babini; A Cachafeiro-Vilar; M Cifuentes-Alvarado; S B Cohen; P E Díaz; L Diaz Soto; C Encalada; B Garro; I A G Sariego; M Guibert-Toledano; V J K Rodriguez; M E L Lopez; A P Ortega; A S Russell; P Santos-Moreno; I S Terán; A Vargas; G Vásquez; R M Xavier; D X Xibillé Firedman; E Mysler; J Kay
Journal:  Clin Rheumatol       Date:  2019-03-27       Impact factor: 2.980

3.  Developing A Minimum Data Set for A Rheumatoid Arthritis Registry in Iran.

Authors:  Mostafa Langarizadeh; Nahid Mehrabi; Tania Azadi; Esmaeil Mehraeen; Arman Ahmadzadeh
Journal:  Mediterr J Rheumatol       Date:  2022-03-31

Review 4.  Barriers towards effective pharmacovigilance systems of biosimilars in rheumatology: A Latin American survey.

Authors:  Gilberto Castañeda-Hernández; Hugo Sandoval; Javier Coindreau; Luis Felipe Rodriguez-Davison; Carlos Pineda
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-05-30       Impact factor: 2.890

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.